Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Spotlight on thrombin inhibitors

Nov. 10, 1997

ReoPro cleared in U.S. for expanded labeling

Nov. 7, 1997

Saruplase efficacy demonstrated in large patient study

Nov. 7, 1997

PEG-hirudin compared to established antithrombotic agents

Nov. 7, 1997

Akzo Nobel prepares two series of thrombin inhibitors

Nov. 7, 1997

Lefradafiban: oral prodrug for profound and sustained inhibition of platelet aggregation

Nov. 5, 1997

Teijin licenses new thrombolytic from Schering AG

Nov. 5, 1997

Factor Xa inhibitors prepared at DuPont Merck

Nov. 4, 1997

New orally active thrombin inhibitors from Merck & Co.

Nov. 3, 1997

Ortho discloses peptide serine protease inhibitors

Oct. 30, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.